The deal - all-cash transaction – is Amgen’s first major investment in Turkey since it established an affiliate there in 2010.
Amgen COO Robert A. Bradway said: "Amgen is dedicated to making our innovative medicines available to patients in major markets around the world," adding that "together with MN's staff and management team, we plan to grow our business with high quality and innovative medicines in Turkey and the surrounding region."
MN’s focus on generics fits with Amgen’s increasing focus on that includes the acquisition of Brazil’s Bergamo in 2011 .
